- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06208878
CRISPR CAR T 세포 치료를 받은 피험자에 대한 장기 추적 연구
CRISPR CAR T 세포 치료법으로 치료받은 악성 종양 피험자에 대한 장기 추적 연구
This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies
연구 개요
상세 설명
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study. Subjects who have completed the parent study for the protocol-defined duration, or who have discontinued the parent study early, or who are in secondary follow-up (follow up of subjects with progressive disease or who receive a subsequent line of anticancer therapy) in the parent study may enroll in this LTFU study. This will allow for collection of long-term efficacy data (as applicable) and safety data up to 15 years post-treatment with CRISPR CAR T cellular therapies.
연구 유형
등록 (추정된)
연락처 및 위치
연구 장소
-
-
-
Hamburg, 독일, D-20246
- University Hospital Hamburg-Eppendorf
-
-
-
-
California
-
Duarte, California, 미국, 91010
- City of Hope
-
Los Angeles, California, 미국, 90048
- Cedars Sinai
-
Stanford, California, 미국, 94305
- Stanford
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06510
- Yale New Haven Hospital
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Emory
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- University of Chicago
-
-
Kansas
-
Westwood, Kansas, 미국, 66205
- University of Kansas
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55455
- University of Minnesota
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- Washington University Saint Louis
-
-
New York
-
New York, New York, 미국, 10065
- MSKCC
-
The Bronx, New York, 미국, 10467
- Montefiore Medical Center
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- University of Pennsylvania
-
-
Texas
-
Dallas, Texas, 미국, 75390
- UT Southwestern
-
Houston, Texas, 미국, 77030
- MD Anderson Cancer Center
-
San Antonio, Texas, 미국, 78229
- Methodist Hospital-Sarah Cannon
-
-
Utah
-
Salt Lake City, Utah, 미국, 84112
- University of Utah-Huntsman Cancer Institute
-
-
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G 2M9
- Princess Margaret
-
-
-
-
-
Melbourne, 호주
- Alfred Health
-
Nedlands, 호주, 6009
- Sir Charles Gairdner
-
Richmond, 호주
- Epworth Healthcare
-
-
New South Wales
-
Camperdown, New South Wales, 호주, 2050
- Royal Prince Alfred Hospital
-
-
Victoria
-
Melbourne, Victoria, 호주, 3000
- Peter MacCallum Cancer Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study. Subjects who have completed the parent study for the protocol-defined duration, or who have discontinued the parent study early, or who are in secondary follow-up (follow up of subjects with progressive disease or who receive a subsequent line of anticancer therapy) in the parent study may enroll in this LTFU study. This will allow for collection of long-term efficacy data (as applicable) and safety data up to 15 years post-treatment with CRISPR CAR T cellular therapies.
설명
Inclusion Criteria:
- Able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document.
- Must have received CRISPR CAR T cellular therapy.
Exclusion Criteria:
- There are no specific exclusion criteria.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Non Interventional
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study. |
Safety and Efficacy Assessment |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment.
기간: 15 years
|
The number and percentage of subjects with CRISPR CAR T cellular therapy related SAEs and AESIs will be summarized. |
15 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The overall survival and duration of remission/response following CRISPR CAR T cellular therapy treatment
기간: 15 years
|
Overall survival will be calculated as the time between the initial dose of CRISPR CAR T cellular therapy in the parent study and death due to any cause. Duration of remission/response will be calculated as the time between the first objective response to first disease progression or death due to any cause. |
15 years
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .